risankizumab   Click here for help

GtoPdb Ligand ID: 8922

Synonyms: ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
Approved drug Immunopharmacology Ligand
risankizumab is an approved drug (Japan, FDA & EMA (2019))
Compound class: Antibody
Comment: Risankizumab (research code BI 655066) is a humanised monoclonal antibody targeting interleukin 23A (IL-23A) [11]. It was developed through collaboration between Boehringer Ingelheim and AbbVie for the treatment of autoinflammatory diseases.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (Japan, FDA & EMA (2019))
International Nonproprietary Names Click here for help
INN number INN
10128 risankizumab
Synonyms Click here for help
ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 567
Other databases
GtoPdb PubChem SID 310264703
Search PubMed clinical trials risankizumab
Search PubMed titles risankizumab
Search PubMed titles/abstracts risankizumab